Funds holding CITIUS ONCOLOGY INC
ISIN US17331Y1091 · United States
- Fund holders
- 8
- Of which ETFs
- 1 7 other funds
- Value held
- 586.1K $
- Share of capital
- 0.8 % of 93M shares on Aug 13, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 370,100 | 229.4K $ | 0.40 % | as of Mar 31, 2026 ↗ | |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 164,724 | 102.1K $ | 0.00 % | 0.18 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 93,890 | 105.2K $ | 0.00 % | 0.10 % | as of Feb 28, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 57,297 | 64.2K $ | 0.00 % | 0.06 % | as of Feb 28, 2026 ↗ |
| iShares Micro-Cap ETF iShares Trust | 45,261 | 28.1K $ | 0.00 % | 0.05 % | as of Mar 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 26,290 | 29.4K $ | 0.03 % | as of Feb 28, 2026 ↗ | |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 23,392 | 26.2K $ | 0.03 % | as of Feb 28, 2026 ↗ | |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 2,491 | 1.5K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table counts shares; this one measures what the company weighs inside each fund.
| Fund | Weight in fund | |
|---|---|---|
| iShares Micro-Cap ETF iShares Trust | 0.00 % | as of Mar 31, 2026 ↗ |
| 1290 VT Micro Cap Portfolio EQ Advisors Trust | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each SEC quarterly data set, newest first. The change is read against the quarter before it.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 8 | 0 | 783,445 | +20.8 % |
| 2026Q1 | 8 | +6 | 648,409 | +299.6 % |
| 2025Q4 | 2 | +1 | 162,284 | +690.1 % |
| 2025Q3 | 1 | 0 | 20,539 | 0.0 % |
| 2025Q2 | 1 | 0 | 20,539 | +780.7 % |
| 2025Q1 | 1 | 0 | 2,332 | 0.0 % |
| 2024Q4 | 1 | 2,332 |
Institutional managers
11 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 9,188,855 | 5.7M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 3,835,160 | 2.4M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 264,733 | 164.1K $ | as of Mar 31, 2026 |
| IFP Advisors, Inc | 107,424 | 66.6K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 47,454 | 29.4K $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 45,746 | 28.4K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 42,900 | 26.6K $ | as of Mar 31, 2026 |
| UBS Group AG | 36,840 | 22.8K $ | as of Mar 31, 2026 |
| Arkadios Wealth Advisors | 11,666 | 7.2K $ | as of Mar 31, 2026 |
| OSAIC HOLDINGS, INC. | 10,125 | 6.3K $ | as of Mar 31, 2026 |
| Caitong International Asset Management Co., Ltd | 1 | 1 $ | as of Mar 31, 2026 |
Declared shareholders of CITIUS ONCOLOGY INC
2 beneficial ownership filings. These stakes do not add up: an asset manager filing aggregates its own funds, already counted above.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. | 71.00 % | 66,049,615 | as of May 15, 2026 · SCHEDULE 13D |
| Armistice Capital, LLC and 1 other | 9.99 % | 9,299,917 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding CITIUS ONCOLOGY INC". https://titelia.com/en/stocks/citius-oncology-inc-US17331Y1091